{
  "id": 8716205,
  "title": "Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook",
  "url": "https://urgent.news/2026/09/20/investors-dumped-ionis-pharmaceuticals-stock-but-wall-street-hasnt-8716205",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-20T13:50:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/investors-dumped-ionis-pharmaceuticals-stock-wall-street-hasnt-budged-its-bullish-outlook"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsIonis has six commercial therapies, mostly focused on rare diseases.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook",
        "url": "https://urgent.news/2026/09/20/investors-dumped-ionis-pharmaceuticals-stock-but-wall-street-hasnt",
        "published": "2026-09-20T13:30:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}